Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
ReachMD Faculty

Public Profile

Greg Brown, MD, PhD
Greg Brown, MD, PhD

    Dr. Greg Brown is a professor of medicine in the Cardiology Division at the University of Washington School of Medicine in Seattle, and a diplomate of the American Board of Clinical Lipidology.

    His training includes MIT undergraduate study, medical school and a doctorate in biomedical engineering at Johns Hopkins University, Medical residency at Hopkins and at UC-San Diego. After three years as a clinical associate at the NHLBI (Laboratory of Experimental Atherosclerosis; Don Fry, MD, Director), he took a cardiology fellowship at the University of Washington in Seattle.

    He has served as a clinical investigator at the Los Angeles VA Hospital (1976-79), and as an Established Investigator of the American Heart Association (1979-84). His career accomplishments include pioneering work on intraaortic balloon cardiac assistance, and experimental studies in arterial wall lipid diffusion which won the first Irving H. Page Award (Young Investigator, Arteriosclerosis, AHA, 1978). He is credited with the development of quantitative arteriography, and was Principal Investigator for the first statin clinical endpoint trial, the FATS study of cholesterol-lowering therapy in patients with coronary disease. He is the recipient (1995) of the NIH-NCEP Clinical Science Achievement Award for his studies over the prior decade in cholesterol, coronary disease regression, and plaque stabilization. He and his collaborators at the University of Washington have reported the results of an angiographic trial (HATS) in patients with low HDL cholesterol. The favorable results of HATS trial reflect a recurrent theme in his laboratory’s studies, i.e., that there is substantial benefit from combination therapies that raise HDL and lower LDL-cholesterol. He is the Principal Investigator of the 5-year NHLBI-sponsored clinical trial called AIM-HIGH, which will compare simvastatin plus niacin-ER with simvastatin alone in terms of major cardiovascular events in 3300 patients with established vascular disease and atherogenic dyslipidemia.

    Programs 6/15/21